Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the signing of an authorized agency and technical transfer cooperation agreement with a company based in Bangladesh. The undisclosed Bangladeshi company will collaborate with Kangtai Bio on the 23-valent pneumococcal polysaccharide vaccine semi-finished stock solution. The partnership aims to jointly advance the regulatory filing, oversee the market launch, facilitate technical transfer, and secure a distribution license for the vaccine in Bangladesh, a significant player in the South Asian subcontinent.
This alliance is in line with Kangtai Bio’s ongoing efforts to bolster vaccine accessibility, particularly in countries along the “Belt and Road Initiative” trade and infrastructure network. The company has previously established partnerships with local firms in Pakistan and India, underscoring its commitment to enhancing health outcomes and supporting regional development initiatives.- Flcube.com
